MRTX1133

· Mirati Therapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MRTX1133, covering 2025-04-06 to 2025-04-06. Get the full timeline:

Most recent: Clinical Trial Update: Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation [Phase 1]